Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

Jason K. Lee; Alain Gendron; Michelle Knutson; Niroshan Sriskandarajah; Lawrence Mbuagbaw; Stephen G. Noorduyn

doi:10.1183/23120541.00778-2020

Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

Jason K. Lee, Alain Gendron, Michelle Knutson, Niroshan Sriskandarajah, Lawrence Mbuagbaw, Stephen G. Noorduyn

ERJ Open Research 2021 7: 00778-2020; DOI: 10.1183/23120541.00778-2020

Jason K. Lee

1Evidence Based Medical Educator, Toronto, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Alain Gendron

2AstraZeneca, Mississauga, Canada

3Dept of Medicine, University of Montreal, Quebec, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Alain Gendron

Michelle Knutson

4University of Toronto, Toronto, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Niroshan Sriskandarajah

2AstraZeneca, Mississauga, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lawrence Mbuagbaw

5Dept of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Lawrence Mbuagbaw

Stephen G. Noorduyn

2AstraZeneca, Mississauga, Canada

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
For correspondence: Stephen.noorduyn@astrazeneca.com

Article
Figures & Data
Info & Metrics
PDF

Figures

Download figure
Open in new tab
Download powerpoint
FIGURE 1
a) Kaplan–Meier survival curve for discontinuation. b) Trends in average monthly claims for rescue medications before, during and after use of mepolizumab. Bars represent means and error bars represent standard deviations. OCS: oral corticosteroid; SABA: short-acting β₂-agonist. F-tests were performed for differences between groups.

PreviousNext

Vol 7 Issue 1 Table of Contents

Table of Contents
Index by author

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following Time on therapy and concomitant medication use of mepolizumab in Canada: a retrospective cohort study

Message Subject (Your Name) has sent you a message from European Respiratory Society

Message Body (Your Name) thought you would like to see the European Respiratory Society web site.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.